TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04887792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Study: NCT05393947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education
Description: It is planned to provide education to patients about the side effects of chemotherapy.
Study: NCT06481800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Description: patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
Study: NCT04887792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical gelatin capsules will be prepared by filling with inert excipients.
Study: NCT06411730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days
Study: NCT05134766

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison

Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison
Study: NCT04696913

Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Positive COVID-19 infection
Description: Exposure: Positive COVID-19 infection as determined by RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Positive COVID-19 infection
Description: Exposure: Positive COVID-19 infection as determined by RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Negative COVID-19 infection
Description: Exposure: Negative COVID-19 infection as determined by RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Negative COVID-19 infection
Description: Exposure: Negative COVID-19 infection as determined by RT-PCR
Study: NCT06489899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEGISUS
Description: PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
Study: NCT05399225

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets to lymphocytes ratio and procalcitonin
Description: Platelets to lymphocytes ratio and procalcitonin in sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets to lymphocytes ratio and procalcitonin
Description: Platelets to lymphocytes ratio and procalcitonin in sepsis
Study: NCT05968222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration exercise
Description: Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
Study: NCT04947163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IMT
Description: Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
Study: NCT03454750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: 177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
Study: NCT05159557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited In-Home Technology
Description: Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
Study: NCT04971850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep study
Description: Procedures added by research during PSG :~* SDB screening questionnaires~* Electromyography (EMG) of accessory and abdominal muscles~* Cerebral oxygenation~* Mandibular movements~* Sleep headband (pre-teens and teens) or other connected device~* Automatic PSG analyzes~* Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG.
Study: NCT05019027

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and will be subsequently discontinued.~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol~* sotalol
Study: NCT05457218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IPC80
Description: The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Buffalo Powder
Description: The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)
Study: NCT06057324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based Apps
Description: Families which will use the digital interactive tools to empower parents in their daily dietary choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-based diet toolkit and activities
Description: Families which will receive educational materials and adolescents will perform educational activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy plant-based snacks
Description: Families in which children will include the snacks in their diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Mediterranean-based diet toolkit and activities
Description: Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Healthy plant-based snacks
Description: Families which will use the digital interactive tools and children will include the snacks in their diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-based diet toolkit and activities + Healthy plant-based snacks
Description: Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
Study: NCT06388590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dragons
Description: The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
Study: NCT05603923

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumen Coached PST Intervention.
Description: Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Coached PST Intervention.
Description: Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Optional (delayed) Lumen Coached PST (Waitlist control).
Description: Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
Study: NCT06579586

Intervention type: BEHAVIORAL
Intervention: Survey study
Description: The Parent's State and Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index-3 (AS-3), and Pain Catastrophising Scale for Parents (PPS-PPS) were completed one day before the operation to measure anxiety level.
Study: NCT05947851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 5 and 20 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 10, 50, and 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: 10, 50, and 100 mg tablets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
Study: NCT04773795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoZip System
Description: The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.
Study: NCT05582304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: ACUVUE OASYS 1-Day with HydraLuxe Technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: ACUVUE OASYS 1-Day with HydraLuxe Technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: ACUVUE OASYS 1-Day with HydraLuxe Technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: ACUVUE OASYS 1-Day with HydraLuxe Technology
Study: NCT06553235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: - Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
Study: NCT05177445

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OT+Corticosteroids
Description: Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
Study: NCT06491849

Intervention type: OTHER
Intervention: Peri-implant Condition Evaluation
Description: This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
Study: NCT06201715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: 5mg tofacitinib tablet twice daily
Study: NCT05163106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
Description: Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
Study: NCT05000411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dropping Pills (CDDP)
Description: The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
Study: NCT04794894

Intervention type: BEHAVIORAL
Intervention: outpatient rehabilitation
Description: Treatment provided after completion of inpatient, acute rehabilitation.

Intervention type: BEHAVIORAL
Intervention: outpatient rehabilitation
Description: Treatment provided after completion of inpatient, acute rehabilitation.
Study: NCT04859218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
Study: NCT05138432

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fruit and Vegetable Prescription Voucher
Description: Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fruit and Vegetable Prescription Voucher
Description: Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
Study: NCT04872101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT06057324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks
Description: Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
Study: NCT05284799

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
Description: One single administration intramuscularly at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
Description: One single administration intramuscularly at Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single administration intramuscularly at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One single administration intramuscularly at Day 1
Study: NCT06489782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 1
Description: Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 1
Description: Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 2
Description: Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 2
Description: Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.